These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 31959343)
1. Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models. Ny L; Rizzo LY; Belgrano V; Karlsson J; Jespersen H; Carstam L; Bagge RO; Nilsson LM; Nilsson JA Ann Oncol; 2020 Feb; 31(2):266-273. PubMed ID: 31959343 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models. Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216 [TBL] [Abstract][Full Text] [Related]
3. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice. Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115 [TBL] [Abstract][Full Text] [Related]
4. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse. Ashizawa T; Iizuka A; Nonomura C; Kondou R; Maeda C; Miyata H; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Katano I; Ito M; Akiyama Y Clin Cancer Res; 2017 Jan; 23(1):149-158. PubMed ID: 27458246 [TBL] [Abstract][Full Text] [Related]
5. Spontaneous Post-Transplant Disorders in NOD.Cg- Prkdcscid Il2rgtm1Sug/JicTac (NOG) Mice Engrafted with Patient-Derived Metastatic Melanomas. Radaelli E; Hermans E; Omodho L; Francis A; Vander Borght S; Marine JC; van den Oord J; Amant F PLoS One; 2015; 10(5):e0124974. PubMed ID: 25996609 [TBL] [Abstract][Full Text] [Related]
6. Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models. Okada S; Vaeteewoottacharn K; Kariya R Cells; 2019 Aug; 8(8):. PubMed ID: 31412684 [TBL] [Abstract][Full Text] [Related]
7. Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. Friedman AA; Xia Y; Trippa L; Le LP; Igras V; Frederick DT; Wargo JA; Tanabe KK; Lawrence DP; Neuberg DS; Flaherty KT; Fisher DE Clin Cancer Res; 2017 Aug; 23(16):4680-4692. PubMed ID: 28446504 [No Abstract] [Full Text] [Related]
8. Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes. Marín-Jiménez JA; Capasso A; Lewis MS; Bagby SM; Hartman SJ; Shulman J; Navarro NM; Yu H; Rivard CJ; Wang X; Barkow JC; Geng D; Kar A; Yingst A; Tufa DM; Dolan JT; Blatchford PJ; Freed BM; Torres RM; Davila E; Slansky JE; Pelanda R; Eckhardt SG; Messersmith WA; Diamond JR; Lieu CH; Verneris MR; Wang JH; Kiseljak-Vassiliades K; Pitts TM; Lang J Front Immunol; 2021; 12():607282. PubMed ID: 33854497 [TBL] [Abstract][Full Text] [Related]
9. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. Lin S; Huang G; Cheng L; Li Z; Xiao Y; Deng Q; Jiang Y; Li B; Lin S; Wang S; Wu Q; Yao H; Cao S; Li Y; Liu P; Wei W; Pei D; Yao Y; Wen Z; Zhang X; Wu Y; Zhang Z; Cui S; Sun X; Qian X; Li P MAbs; 2018; 10(8):1301-1311. PubMed ID: 30204048 [TBL] [Abstract][Full Text] [Related]
10. Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses. Yaguchi T; Kobayashi A; Inozume T; Morii K; Nagumo H; Nishio H; Iwata T; Ka Y; Katano I; Ito R; Ito M; Kawakami Y Cell Mol Immunol; 2018 Nov; 15(11):953-962. PubMed ID: 29151581 [TBL] [Abstract][Full Text] [Related]
11. The first Japanese biobank of patient-derived pediatric acute lymphoblastic leukemia xenograft models. Tanaka K; Kato I; Dobashi Y; Imai JI; Mikami T; Kubota H; Ueno H; Ito M; Ogawa S; Nakahata T; Takita J; Toyoda H; Ogawa C; Adachi S; Watanabe S; Goto H Cancer Sci; 2022 Nov; 113(11):3814-3825. PubMed ID: 35879192 [TBL] [Abstract][Full Text] [Related]
12. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857 [TBL] [Abstract][Full Text] [Related]
13. Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts. Bhadury J; Einarsdottir BO; Podraza A; Bagge RO; Stierner U; Ny L; Dávila López M; Nilsson JA Oncotarget; 2016 Apr; 7(17):23801-11. PubMed ID: 27009863 [TBL] [Abstract][Full Text] [Related]
14. Genetics and Therapeutic Responses to Tumor-Infiltrating Lymphocyte Therapy of Pancreatic Cancer Patient-Derived Xenograft Models. Nilsson LM; Vilhav C; Karlsson JW; Fagman JB; Giglio D; Engström CE; Naredi P; Nilsson JA Gastro Hep Adv; 2022; 1(6):1037-1048. PubMed ID: 39131259 [TBL] [Abstract][Full Text] [Related]
15. The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line. Akiyama Y; Nonomura C; Ashizawa T; Iizuka A; Kondou R; Miyata H; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Asai A; Ito M; Kiyohara Y; Yamaguchi K Immunol Lett; 2017 Oct; 190():20-25. PubMed ID: 28716484 [TBL] [Abstract][Full Text] [Related]
16. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. Wang J; Fei K; Jing H; Wu Z; Wu W; Zhou S; Ni H; Chen B; Xiong Y; Liu Y; Peng B; Yu D; Jiang H; Liu J MAbs; 2019; 11(8):1443-1451. PubMed ID: 31402780 [TBL] [Abstract][Full Text] [Related]
17. S100A4 expression with reduced E-cadherin expression predicts distant metastasis of human malignant melanoma cell lines in the NOD/SCID/gammaCnull (NOG) mouse model. Ikoma N; Yamazaki H; Abe Y; Oida Y; Ohnishi Y; Suemizu H; Matsumoto H; Matsuyama T; Ohta Y; Ozawa A; Ueyama Y; Nakamura M Oncol Rep; 2005 Sep; 14(3):633-7. PubMed ID: 16077966 [TBL] [Abstract][Full Text] [Related]
18. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models. Pyo KH; Kim JH; Lee JM; Kim SE; Cho JS; Lim SM; Cho BC Lung Cancer; 2019 Jan; 127():112-121. PubMed ID: 30642538 [TBL] [Abstract][Full Text] [Related]
19. NOG-hIL-4-Tg, a new humanized mouse model for producing tumor antigen-specific IgG antibody by peptide vaccination. Kametani Y; Katano I; Miyamoto A; Kikuchi Y; Ito R; Muguruma Y; Tsuda B; Habu S; Tokuda Y; Ando K; Ito M PLoS One; 2017; 12(6):e0179239. PubMed ID: 28617827 [TBL] [Abstract][Full Text] [Related]
20. A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Krepler C; Sproesser K; Brafford P; Beqiri M; Garman B; Xiao M; Shannan B; Watters A; Perego M; Zhang G; Vultur A; Yin X; Liu Q; Anastopoulos IN; Wubbenhorst B; Wilson MA; Xu W; Karakousis G; Feldman M; Xu X; Amaravadi R; Gangadhar TC; Elder DE; Haydu LE; Wargo JA; Davies MA; Lu Y; Mills GB; Frederick DT; Barzily-Rokni M; Flaherty KT; Hoon DS; Guarino M; Bennett JJ; Ryan RW; Petrelli NJ; Shields CL; Terai M; Sato T; Aplin AE; Roesch A; Darr D; Angus S; Kumar R; Halilovic E; Caponigro G; Jeay S; Wuerthner J; Walter A; Ocker M; Boxer MB; Schuchter L; Nathanson KL; Herlyn M Cell Rep; 2017 Nov; 21(7):1953-1967. PubMed ID: 29141225 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]